TruScan RM - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TruScan RM


Thermo Scientific portable solutions deliver specialized identification and analysis of raw materials for the highly regulated global pharmaceutical industry.

With greater than 650 GMP facility installations worldwide, we’ve successfully implemented our solutions into the top pharmaceutical companies and regulatory enforcement agencies worldwide – enabling them to increase productivity and realize a rapid return on their investment.

We are more than the leading provider of portable analytical instruments. We are a true partner, delivering expertise and solutions to improve processes, reduce risk & costs, and achieve competitive advantage.

Developed with in-depth pharmaceutical industry experience, Thermo Scientific handheld analyzers provide manufacturers with a portable solution to achieve quality initiatives throughout the manufacturing process.
The Thermo Scientific TruScan RM, based on Raman spectroscopy, and the Thermo Scientific microPHAZIR RX, based on Near-Infrared spectroscopy, are simple to use and enable on-the-spot, actionable Pass-Fail results within seconds.
 
Both analyzers are 21 CFR part 11 compliant and meet the requirements of global pharmacopeias.  Our handheld solutions are used by 24 of the top 25 global pharmaceutical manufacturers, driving significant time and cost savings. 

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

 

Thermo Scientific – Portable Analytical Instruments

Website: www.thermoscientific.com/quality

E-mail: sales.chemid@thermofisher.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here